Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD

Chart, Trading, Forex, Analysis, Tablet, Pc

Image Source: Pixabay

Below are how each constituent stock performed last week, in descending order, and YTD, plus any recent news, commentary, and/or analysis for each company:

  1. atai Life Sciences (ATAI): UP 24.4% last week; UP 73.8% YTD
  2. Mind Medicine (MNMD): UP 17.0% last week; UP 200.5% YTD
  3. Compass Pathways (CMPS): UP 14.2% last week; UP 8.6% YTD
  4. GH Research (GHRS): UP 4.5% last week; UP 92.1% YTD
    • is primarily focused on the use of mebufotenin, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine.
    • Latest News, Commentary and/or Analysis: None
  5. Incannex Healthcare (IXHL): DOWN 9.5% last week; DOWN 30.0% YTD
    • is researching and developing therapies and products with the world's largest portfolio of medicinal cannabinoid and psychedelic pharmaceutical products.
    • Latest News, Commentary and/or Analysis: None

The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 10.0%, on average, last week and are now UP 53.9% YTD.

More By This Author:

Tilray's Q3 Financials Disappoint: Stock Declines 31%
Hope Springs Eternal: Canadian Cannabis LPs Index Up 20% Last Week
American Cannabis MSO Stocks Index Flat Last Week; Up 51% YTD

Disclosure: None

This article has been composed with the exclusive application of the human intelligence (HI) of the author. No artificial intelligence (AI) technology has been deployed. ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.